More on Intralymphatic injection of Autoantigen in Type 1 Diabetes

New England Journal of Medicine

Volumn 377, Issue 4, 2017, Pages 403-405

  Ludvigsson, Johnny ^a   Tavira, Beatriz ^a   Casas, Rosaura ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; C PEPTIDE; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE; GLYCOSYLATED HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 5; PLACEBO; TUMOR NECROSIS FACTOR; AUTOANTIGEN;

CYTOKINE RELEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; PRIORITY JOURNAL; IMMUNOLOGY; INTRALYMPHATIC DRUG ADMINISTRATION;

AUTOANTIGENS; DIABETES MELLITUS, TYPE 1; HUMANS; INJECTIONS, INTRALYMPHATIC;

EID: 85026322588     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1703468     Document Type: Letter

References (4)

1. Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011;378:319-27.
2. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-9.
3. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-20.
4. Axelsson S, Chéramy M, Akerman L, Pihl M, Ludvigsson J, Casas R. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial. Diabetes Care 2013;36:3418-24.